Benlysta 200 MG/ML autoinjectml
Ended Awarded Last action
- Contract number
- SPE2DR26FGL1C
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,249
Award facts
- Contract value 100% obligated
- $3,248.66 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $3,248.66 to AmerisourceBergen Drug Corp on December 10, 2025, for the supply of Benlysta 200 mg/ml auto-injectors. The contract is a firm fixed price delivery order with an ultimate completion date of January 2, 2026, and represents a non-competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical federal medical procurement vendor serving military and veteran healthcare systems. This delivery order is issued under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 comprehensive global pharmaceutical support vehicle running through December 2026 that enables the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide.
Benlysta (belimumab) is a monoclonal antibody immunosuppressant primarily used in the treatment of systemic lupus erythematosus (SLE) and lupus nephritis. This delivery order reflects the Defense Health Agency's ongoing need for specialized pharmaceutical therapeutics to support active duty service members and military beneficiaries. AmerisourceBergen's role as a prime vendor under the DLA's pharmaceutical framework demonstrates the agency's reliance on established distribution channels to ensure timely and efficient delivery of critical immunological treatments across the military healthcare system.
Quick answers
Who was awarded contract SPE2DR26FGL1C?
SPE2DR26FGL1C was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on December 10, 2025.
How much is contract SPE2DR26FGL1C worth?
The government has obligated $3,249 on SPE2DR26FGL1C.
Is contract SPE2DR26FGL1C an order under another contract?
Yes. SPE2DR26FGL1C is a delivery order under SPE2DR25D1002, an indefinite delivery contract.
Was contract SPE2DR26FGL1C competed?
The extent of competition for SPE2DR26FGL1C was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award